To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)

NCT01768572 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

202

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

DRUG: sarilumab SAR153191 (REGN88)
DRUG: tocilizumab
DRUG: hydroxychloroquine
DRUG: methotrexate
DRUG: sulfasalazine
DRUG: leflunomide
DRUG: subcutaneous placebo
DRUG: intravenous placebo

Sponsor

Sanofi

Collaborators

[object Object]